LCE3A: A Potential Drug Target and Biomarker (G353142)

Target Name: LCE3A

NCBI ID: G353142

LCE3A

LCE3A: A Potential Drug Target and Biomarker

Late envelope protein 13 (LCE3A) is a protein that is expressed in various cell types of the human body, including epithelial, endothelial, and neural cells. LCE3A is a member of the late envelope family of proteins, which are involved in the regulation of cell-cell adhesion, migration, and signaling. The late envelope family of proteins has been identified as potential drug targets in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In this article, we will discuss the potential drug target of LCE3A and its potential as a biomarker for various diseases.

Potential Drug Target: LCE3A

LCE3A has been identified as a potential drug target due to its involvement in cell-cell adhesion and migration. LCE3A is a protein that is involved in the regulation of tight junction formation, which is a critical process that helps to maintain the integrity of the blood-brain barrier. tight junction formation is also involved in the regulation of cell-cell adhesion, which is critical for the maintenance of tissue structure and function.

LCE3A has also been shown to be involved in the regulation of migration. During the development and progression of cancer, LCE3A has been shown to be involved in the regulation of cell migration, which is critical for the formation of tumors.

In addition to its involvement in cell-cell adhesion and migration, LCE3A has also been shown to play a role in the regulation of cell signaling. LCE3A has been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway, which is involved in the regulation of cell growth, differentiation, and survival.

Potential Biomarker: LCE3A

LCE3A has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, LCE3A has been shown to be involved in the regulation of cell signaling, including the regulation of the TGF-β pathway. LCE3A has also been shown to be involved in the regulation of cell-cell adhesion, which is critical for the maintenance of cancer cell survival.

In neurodegenerative diseases, LCE3A has been shown to be involved in the regulation of cell signaling, including the regulation of the TGF-β pathway. LCE3A has also been shown to be involved in the regulation of cell-cell adhesion, which is critical for the maintenance of neural cell structure and function.

In autoimmune disorders, LCE3A has been shown to be involved in the regulation of cell signaling, including the regulation of the TGF-β pathway. LCE3A has also been shown to be involved in the regulation of cell-cell adhesion, which is critical for the maintenance of immune cell function.

Conclusion

In this article, we have discussed the potential drug target of LCE3A and its potential as a biomarker for various diseases. LCE3A is a protein that is involved in the regulation of cell-cell adhesion and migration, as well as the regulation of cell signaling. Its potential drug target status and biomarker potential make it an attractive target for future research and development. Further studies are needed to fully understand the role of LCE3A in disease progression and to develop effective treatments.

Protein Name: Late Cornified Envelope 3A

Functions: A structural component of the cornified envelope of the stratum corneum involved in innate cutaneous host defense (Probable). Possesses defensin-like antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria, both aerobic and anaerobic species. Upon inflammation, may regulate skin barrier repair by shaping cutaneous microbiota composition and immune response to bacterial antigens (PubMed:28634035)

The "LCE3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets